APO Research
Talk to an analyst

APO RESEARCH · REPORT

Filgrastim and Biosimilars

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Filgrastim and Biosimilars Market Outlook and Growth Opportunities 2026

29 December 2025205 pages

Choose your research edition.

Industry ResearchFilgrastim and Biosimilars Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Filgrastim and Biosimilars Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Filgrastim and Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Filgrastim and Biosimilars Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Filgrastim and Biosimilars Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Filgrastim and Biosimilars market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Filgrastim and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Filgrastim and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Filgrastim and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Filgrastim and Biosimilars market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Filgrastim and Biosimilars market include Changchun GeneScience Pharmaceutical, CSPC Baike Biopharma, Shanghai Sunway Biotech, Amoytop Biotech, Qilu Pharmaceutical, Kexing Biopharm, Jiangsu Wuzhong Pharmaceutical, North China Pharmaceutical and Hangzhou Jiuyuan Gene Engineering, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Filgrastim and Biosimilars market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Filgrastim and Biosimilars and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Filgrastim and Biosimilars sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Filgrastim and Biosimilars market size, projected growth trends, production technologies, key applications, and end-use industries.

Filgrastim and Biosimilars Segment by Company

Changchun GeneScience Pharmaceutical

CSPC Baike Biopharma

Shanghai Sunway Biotech

Amoytop Biotech

Qilu Pharmaceutical

Kexing Biopharm

Jiangsu Wuzhong Pharmaceutical

North China Pharmaceutical

Hangzhou Jiuyuan Gene Engineering

Harbin Pharmaceutical Group

Chengdu Institute of Biological Products

SL Pharm

Teva

Tanvex BioPharma

Sandoz

Pfizer

Kashiv BioSciences

Amgen

Filgrastim and Biosimilars Segment by Type

Single-use Vials

Prefilled Syringes

Filgrastim and Biosimilars Segment by Application

Hospital and Clinic

Pharmacy

Other

Filgrastim and Biosimilars Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Filgrastim and Biosimilars status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Filgrastim and Biosimilars market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Filgrastim and Biosimilars significant trends, drivers, influence factors in global and regions.

6. To analyze Filgrastim and Biosimilars competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Filgrastim and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Filgrastim and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Filgrastim and Biosimilars.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Filgrastim and Biosimilars market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Filgrastim and Biosimilars industry.

Chapter 3: Detailed analysis of Filgrastim and Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Filgrastim and Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Filgrastim and Biosimilars in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Filgrastim and Biosimilars Industry Trends Table 2. Filgrastim and Biosimilars Industry Drivers Table 3. Filgrastim and Biosimilars Industry Opportunities and Challenges Table 4. Filgrastim and Biosimilars Industry Restraints Table 5. Global Filgrastim and Biosimilars Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Filgrastim and Biosimilars Revenue Share by Company (2021-2026) Table 7. Global Filgrastim and Biosimilars Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Filgrastim and Biosimilars Sales Volume Share by Company (2021-2026) Table 9. Global Filgrastim and Biosimilars Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Filgrastim and Biosimilars Company Ranking, (2024-2026) & (USD Million) Table 11. Global Filgrastim and Biosimilars Key Company Manufacturing Base & Headquarters Table 12. Global Filgrastim and Biosimilars Company, Product Type & Application Table 13. Global Filgrastim and Biosimilars Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Filgrastim and Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Single-use Vials Table 18. Significant Companies of Prefilled Syringes Table 19. Global Filgrastim and Biosimilars Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Filgrastim and Biosimilars Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Filgrastim and Biosimilars Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Filgrastim and Biosimilars Sales Volume Share by Type (2021-2026) Table 23. Global Filgrastim and Biosimilars Sales Volume Share by Type (2027-2032) Table 24. Global Filgrastim and Biosimilars Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Filgrastim and Biosimilars Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Filgrastim and Biosimilars Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Filgrastim and Biosimilars Sales Value Share by Type (2021-2026) Table 28. Global Filgrastim and Biosimilars Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital and Clinic Table 30. Significant Companies of Pharmacy Table 31. Significant Companies of Other Table 32. Global Filgrastim and Biosimilars Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Filgrastim and Biosimilars Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Filgrastim and Biosimilars Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Filgrastim and Biosimilars Sales Volume Share by Application (2021-2026) Table 36. Global Filgrastim and Biosimilars Sales Volume Share by Application (2027-2032) Table 37. Global Filgrastim and Biosimilars Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Filgrastim and Biosimilars Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Filgrastim and Biosimilars Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Filgrastim and Biosimilars Sales Value Share by Application (2021-2026) Table 41. Global Filgrastim and Biosimilars Sales Value Share by Application (2027-2032) Table 42. Global Filgrastim and Biosimilars Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Filgrastim and Biosimilars Sales by Region (2021-2026) & (K Units) Table 44. Global Filgrastim and Biosimilars Sales Market Share by Region (2021-2026) Table 45. Global Filgrastim and Biosimilars Sales by Region (2027-2032) & (K Units) Table 46. Global Filgrastim and Biosimilars Sales Market Share by Region (2027-2032) Table 47. Global Filgrastim and Biosimilars Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Filgrastim and Biosimilars Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Filgrastim and Biosimilars Sales Value Share by Region (2021-2026) Table 50. Global Filgrastim and Biosimilars Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Filgrastim and Biosimilars Sales Value Share by Region (2027-2032) Table 52. Global Filgrastim and Biosimilars Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Filgrastim and Biosimilars Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Filgrastim and Biosimilars Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Filgrastim and Biosimilars Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Filgrastim and Biosimilars Sales by Country (2021-2026) & (K Units) Table 57. Global Filgrastim and Biosimilars Sales Market Share by Country (2021-2026) Table 58. Global Filgrastim and Biosimilars Sales by Country (2027-2032) & (K Units) Table 59. Global Filgrastim and Biosimilars Sales Market Share by Country (2027-2032) Table 60. Global Filgrastim and Biosimilars Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Filgrastim and Biosimilars Sales Value Market Share by Country (2021-2026) Table 62. Global Filgrastim and Biosimilars Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Filgrastim and Biosimilars Sales Value Market Share by Country (2027-2032) Table 64. Changchun GeneScience Pharmaceutical Company Information Table 65. Changchun GeneScience Pharmaceutical Business Overview Table 66. Changchun GeneScience Pharmaceutical Filgrastim and Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Changchun GeneScience Pharmaceutical Filgrastim and Biosimilars Product Portfolio Table 68. Changchun GeneScience Pharmaceutical Recent Development Table 69. CSPC Baike Biopharma Company Information Table 70. CSPC Baike Biopharma Business Overview Table 71. CSPC Baike Biopharma Filgrastim and Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. CSPC Baike Biopharma Filgrastim and Biosimilars Product Portfolio Table 73. CSPC Baike Biopharma Recent Development Table 74. Shanghai Sunway Biotech Company Information Table 75. Shanghai Sunway Biotech Business Overview Table 76. Shanghai Sunway Biotech Filgrastim and Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Shanghai Sunway Biotech Filgrastim and Biosimilars Product Portfolio Table 78. Shanghai Sunway Biotech Recent Development Table 79. Amoytop Biotech Company Information Table 80. Amoytop Biotech Business Overview Table 81. Amoytop Biotech Filgrastim and Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Amoytop Biotech Filgrastim and Biosimilars Product Portfolio Table 83. Amoytop Biotech Recent Development Table 84. Qilu Pharmaceutical Company Information Table 85. Qilu Pharmaceutical Business Overview Table 86. Qilu Pharmaceutical Filgrastim and Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Qilu Pharmaceutical Filgrastim and Biosimilars Product Portfolio Table 88. Qilu Pharmaceutical Recent Development Table 89. Kexing Biopharm Company Information Table 90. Kexing Biopharm Business Overview Table 91. Kexing Biopharm Filgrastim and Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Kexing Biopharm Filgrastim and Biosimilars Product Portfolio Table 93. Kexing Biopharm Recent Development Table 94. Jiangsu Wuzhong Pharmaceutical Company Information Table 95. Jiangsu Wuzhong Pharmaceutical Business Overview Table 96. Jiangsu Wuzhong Pharmaceutical Filgrastim and Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Jiangsu Wuzhong Pharmaceutical Filgrastim and Biosimilars Product Portfolio Table 98. Jiangsu Wuzhong Pharmaceutical Recent Development Table 99. North China Pharmaceutical Company Information Table 100. North China Pharmaceutical Business Overview Table 101. North China Pharmaceutical Filgrastim and Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. North China Pharmaceutical Filgrastim and Biosimilars Product Portfolio Table 103. North China Pharmaceutical Recent Development Table 104. Hangzhou Jiuyuan Gene Engineering Company Information Table 105. Hangzhou Jiuyuan Gene Engineering Business Overview Table 106. Hangzhou Jiuyuan Gene Engineering Filgrastim and Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Hangzhou Jiuyuan Gene Engineering Filgrastim and Biosimilars Product Portfolio Table 108. Hangzhou Jiuyuan Gene Engineering Recent Development Table 109. Harbin Pharmaceutical Group Company Information Table 110. Harbin Pharmaceutical Group Business Overview Table 111. Harbin Pharmaceutical Group Filgrastim and Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Harbin Pharmaceutical Group Filgrastim and Biosimilars Product Portfolio Table 113. Harbin Pharmaceutical Group Recent Development Table 114. Chengdu Institute of Biological Products Company Information Table 115. Chengdu Institute of Biological Products Business Overview Table 116. Chengdu Institute of Biological Products Filgrastim and Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Chengdu Institute of Biological Products Filgrastim and Biosimilars Product Portfolio Table 118. Chengdu Institute of Biological Products Recent Development Table 119. SL Pharm Company Information Table 120. SL Pharm Business Overview Table 121. SL Pharm Filgrastim and Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. SL Pharm Filgrastim and Biosimilars Product Portfolio Table 123. SL Pharm Recent Development Table 124. Teva Company Information Table 125. Teva Business Overview Table 126. Teva Filgrastim and Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Teva Filgrastim and Biosimilars Product Portfolio Table 128. Teva Recent Development Table 129. Tanvex BioPharma Company Information Table 130. Tanvex BioPharma Business Overview Table 131. Tanvex BioPharma Filgrastim and Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Tanvex BioPharma Filgrastim and Biosimilars Product Portfolio Table 133. Tanvex BioPharma Recent Development Table 134. Sandoz Company Information Table 135. Sandoz Business Overview Table 136. Sandoz Filgrastim and Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Sandoz Filgrastim and Biosimilars Product Portfolio Table 138. Sandoz Recent Development Table 139. Pfizer Company Information Table 140. Pfizer Business Overview Table 141. Pfizer Filgrastim and Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Pfizer Filgrastim and Biosimilars Product Portfolio Table 143. Pfizer Recent Development Table 144. Kashiv BioSciences Company Information Table 145. Kashiv BioSciences Business Overview Table 146. Kashiv BioSciences Filgrastim and Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 147. Kashiv BioSciences Filgrastim and Biosimilars Product Portfolio Table 148. Kashiv BioSciences Recent Development Table 149. Amgen Company Information Table 150. Amgen Business Overview Table 151. Amgen Filgrastim and Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 152. Amgen Filgrastim and Biosimilars Product Portfolio Table 153. Amgen Recent Development Table 154. Key Raw Materials Table 155. Raw Materials Key Suppliers Table 156. Filgrastim and Biosimilars Distributors List Table 157. Filgrastim and Biosimilars Customers List Table 158. Research Programs/Design for This Report Table 159. Authors List of This Report Table 160. Secondary Sources Table 161. Primary Sources List of Figures Figure 1. Filgrastim and Biosimilars Product Image Figure 2. Global Filgrastim and Biosimilars Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Filgrastim and Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 4. Global Filgrastim and Biosimilars Sales (2021-2032) & (K Units) Figure 5. Global Filgrastim and Biosimilars Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Filgrastim and Biosimilars Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Single-use Vials Image Figure 10. Prefilled Syringes Image Figure 11. Global Filgrastim and Biosimilars Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Filgrastim and Biosimilars Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Filgrastim and Biosimilars Sales Volume Share by Type (2021-2032) Figure 14. Global Filgrastim and Biosimilars Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Filgrastim and Biosimilars Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Filgrastim and Biosimilars Sales Value Share by Type (2021-2032) Figure 17. Hospital and Clinic Image Figure 18. Pharmacy Image Figure 19. Other Image Figure 20. Global Filgrastim and Biosimilars Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Filgrastim and Biosimilars Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Filgrastim and Biosimilars Sales Volume Share by Application (2021-2032) Figure 23. Global Filgrastim and Biosimilars Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Filgrastim and Biosimilars Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Filgrastim and Biosimilars Sales Value Share by Application (2021-2032) Figure 26. Global Filgrastim and Biosimilars Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Filgrastim and Biosimilars Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Filgrastim and Biosimilars Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Filgrastim and Biosimilars Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Filgrastim and Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 31. North America Filgrastim and Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Filgrastim and Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Filgrastim and Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Filgrastim and Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Filgrastim and Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Filgrastim and Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 37. South America Filgrastim and Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Filgrastim and Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Filgrastim and Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Filgrastim and Biosimilars Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Filgrastim and Biosimilars Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Single-use Vials
  • Prefilled Syringes
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • Changchun GeneScience Pharmaceutical
  • CSPC Baike Biopharma
  • Shanghai Sunway Biotech
  • Amoytop Biotech
  • Qilu Pharmaceutical
  • Kexing Biopharm
  • Jiangsu Wuzhong Pharmaceutical
  • North China Pharmaceutical
  • Hangzhou Jiuyuan Gene Engineering
  • Harbin Pharmaceutical Group
  • Chengdu Institute of Biological Products
  • SL Pharm
  • Teva
  • Tanvex BioPharma
  • Sandoz
  • Pfizer
  • Kashiv BioSciences
  • Amgen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Filgrastim and Biosimilars Sales Value (2021-2032)
  4. 1.2.2 Global Filgrastim and Biosimilars Sales Volume (2021-2032)
  5. 1.2.3 Global Filgrastim and Biosimilars Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Filgrastim and Biosimilars Market Dynamics
  1. 2.1 Filgrastim and Biosimilars Industry Trends
  2. 2.2 Filgrastim and Biosimilars Industry Drivers
  3. 2.3 Filgrastim and Biosimilars Industry Opportunities and Challenges
  4. 2.4 Filgrastim and Biosimilars Industry Restraints
3 Filgrastim and Biosimilars Market by Company
  1. 3.1 Global Filgrastim and Biosimilars Company Revenue Ranking in 2025
  2. 3.2 Global Filgrastim and Biosimilars Revenue by Company (2021-2026)
  3. 3.3 Global Filgrastim and Biosimilars Sales Volume by Company (2021-2026)
  4. 3.4 Global Filgrastim and Biosimilars Average Price by Company (2021-2026)
  5. 3.5 Global Filgrastim and Biosimilars Company Ranking (2024-2026)
  6. 3.6 Global Filgrastim and Biosimilars Company Manufacturing Base and Headquarters
  7. 3.7 Global Filgrastim and Biosimilars Company Product Type and Application
  8. 3.8 Global Filgrastim and Biosimilars Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Filgrastim and Biosimilars Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Filgrastim and Biosimilars Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Filgrastim and Biosimilars Market by Type
  1. 4.1 Filgrastim and Biosimilars Type Introduction
  2. 4.1.1 Single-use Vials
  3. 4.1.2 Prefilled Syringes
  4. 4.2 Global Filgrastim and Biosimilars Sales Volume by Type
  5. 4.2.1 Global Filgrastim and Biosimilars Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Filgrastim and Biosimilars Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Filgrastim and Biosimilars Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Filgrastim and Biosimilars Sales Value by Type
  9. 4.3.1 Global Filgrastim and Biosimilars Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Filgrastim and Biosimilars Sales Value by Type (2021-2032)
  11. 4.3.3 Global Filgrastim and Biosimilars Sales Value Share by Type (2021-2032)
5 Filgrastim and Biosimilars Market by Application
  1. 5.1 Filgrastim and Biosimilars Application Introduction
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Filgrastim and Biosimilars Sales Volume by Application
  6. 5.2.1 Global Filgrastim and Biosimilars Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Filgrastim and Biosimilars Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Filgrastim and Biosimilars Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Filgrastim and Biosimilars Sales Value by Application
  10. 5.3.1 Global Filgrastim and Biosimilars Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Filgrastim and Biosimilars Sales Value by Application (2021-2032)
  12. 5.3.3 Global Filgrastim and Biosimilars Sales Value Share by Application (2021-2032)
6 Filgrastim and Biosimilars Regional Sales and Value Analysis
  1. 6.1 Global Filgrastim and Biosimilars Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Filgrastim and Biosimilars Sales by Region (2021-2032)
  3. 6.2.1 Global Filgrastim and Biosimilars Sales by Region: 2021-2026
  4. 6.2.2 Global Filgrastim and Biosimilars Sales by Region (2027-2032)
  5. 6.3 Global Filgrastim and Biosimilars Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Filgrastim and Biosimilars Sales Value by Region (2021-2032)
  7. 6.4.1 Global Filgrastim and Biosimilars Sales Value by Region: 2021-2026
  8. 6.4.2 Global Filgrastim and Biosimilars Sales Value by Region (2027-2032)
  9. 6.5 Global Filgrastim and Biosimilars Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Filgrastim and Biosimilars Sales Value (2021-2032)
  12. 6.6.2 North America Filgrastim and Biosimilars Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Filgrastim and Biosimilars Sales Value (2021-2032)
  15. 6.7.2 Europe Filgrastim and Biosimilars Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Filgrastim and Biosimilars Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Filgrastim and Biosimilars Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Filgrastim and Biosimilars Sales Value (2021-2032)
  21. 6.9.2 South America Filgrastim and Biosimilars Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Filgrastim and Biosimilars Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Filgrastim and Biosimilars Sales Value Share by Country, 2025 VS 2032
7 Filgrastim and Biosimilars Country-level Sales and Value Analysis
  1. 7.1 Global Filgrastim and Biosimilars Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Filgrastim and Biosimilars Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Filgrastim and Biosimilars Sales by Country (2021-2032)
  4. 7.3.1 Global Filgrastim and Biosimilars Sales by Country (2021-2026)
  5. 7.3.2 Global Filgrastim and Biosimilars Sales by Country (2027-2032)
  6. 7.4 Global Filgrastim and Biosimilars Sales Value by Country (2021-2032)
  7. 7.4.1 Global Filgrastim and Biosimilars Sales Value by Country (2021-2026)
  8. 7.4.2 Global Filgrastim and Biosimilars Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Filgrastim and Biosimilars Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Filgrastim and Biosimilars Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Filgrastim and Biosimilars Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Changchun GeneScience Pharmaceutical
  2. 8.1.1 Changchun GeneScience Pharmaceutical Company Information
  3. 8.1.2 Changchun GeneScience Pharmaceutical Business Overview
  4. 8.1.3 Changchun GeneScience Pharmaceutical Filgrastim and Biosimilars Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Changchun GeneScience Pharmaceutical Filgrastim and Biosimilars Product Portfolio
  6. 8.1.5 Changchun GeneScience Pharmaceutical Recent Developments
  7. 8.2 CSPC Baike Biopharma
  8. 8.2.1 CSPC Baike Biopharma Company Information
  9. 8.2.2 CSPC Baike Biopharma Business Overview
  10. 8.2.3 CSPC Baike Biopharma Filgrastim and Biosimilars Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 CSPC Baike Biopharma Filgrastim and Biosimilars Product Portfolio
  12. 8.2.5 CSPC Baike Biopharma Recent Developments
  13. 8.3 Shanghai Sunway Biotech
  14. 8.3.1 Shanghai Sunway Biotech Company Information
  15. 8.3.2 Shanghai Sunway Biotech Business Overview
  16. 8.3.3 Shanghai Sunway Biotech Filgrastim and Biosimilars Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Shanghai Sunway Biotech Filgrastim and Biosimilars Product Portfolio
  18. 8.3.5 Shanghai Sunway Biotech Recent Developments
  19. 8.4 Amoytop Biotech
  20. 8.4.1 Amoytop Biotech Company Information
  21. 8.4.2 Amoytop Biotech Business Overview
  22. 8.4.3 Amoytop Biotech Filgrastim and Biosimilars Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Amoytop Biotech Filgrastim and Biosimilars Product Portfolio
  24. 8.4.5 Amoytop Biotech Recent Developments
  25. 8.5 Qilu Pharmaceutical
  26. 8.5.1 Qilu Pharmaceutical Company Information
  27. 8.5.2 Qilu Pharmaceutical Business Overview
  28. 8.5.3 Qilu Pharmaceutical Filgrastim and Biosimilars Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Qilu Pharmaceutical Filgrastim and Biosimilars Product Portfolio
  30. 8.5.5 Qilu Pharmaceutical Recent Developments
  31. 8.6 Kexing Biopharm
  32. 8.6.1 Kexing Biopharm Company Information
  33. 8.6.2 Kexing Biopharm Business Overview
  34. 8.6.3 Kexing Biopharm Filgrastim and Biosimilars Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Kexing Biopharm Filgrastim and Biosimilars Product Portfolio
  36. 8.6.5 Kexing Biopharm Recent Developments
  37. 8.7 Jiangsu Wuzhong Pharmaceutical
  38. 8.7.1 Jiangsu Wuzhong Pharmaceutical Company Information
  39. 8.7.2 Jiangsu Wuzhong Pharmaceutical Business Overview
  40. 8.7.3 Jiangsu Wuzhong Pharmaceutical Filgrastim and Biosimilars Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Jiangsu Wuzhong Pharmaceutical Filgrastim and Biosimilars Product Portfolio
  42. 8.7.5 Jiangsu Wuzhong Pharmaceutical Recent Developments
  43. 8.8 North China Pharmaceutical
  44. 8.8.1 North China Pharmaceutical Company Information
  45. 8.8.2 North China Pharmaceutical Business Overview
  46. 8.8.3 North China Pharmaceutical Filgrastim and Biosimilars Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 North China Pharmaceutical Filgrastim and Biosimilars Product Portfolio
  48. 8.8.5 North China Pharmaceutical Recent Developments
  49. 8.9 Hangzhou Jiuyuan Gene Engineering
  50. 8.9.1 Hangzhou Jiuyuan Gene Engineering Company Information
  51. 8.9.2 Hangzhou Jiuyuan Gene Engineering Business Overview
  52. 8.9.3 Hangzhou Jiuyuan Gene Engineering Filgrastim and Biosimilars Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Hangzhou Jiuyuan Gene Engineering Filgrastim and Biosimilars Product Portfolio
  54. 8.9.5 Hangzhou Jiuyuan Gene Engineering Recent Developments
  55. 8.10 Harbin Pharmaceutical Group
  56. 8.10.1 Harbin Pharmaceutical Group Company Information
  57. 8.10.2 Harbin Pharmaceutical Group Business Overview
  58. 8.10.3 Harbin Pharmaceutical Group Filgrastim and Biosimilars Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Harbin Pharmaceutical Group Filgrastim and Biosimilars Product Portfolio
  60. 8.10.5 Harbin Pharmaceutical Group Recent Developments
  61. 8.11 Chengdu Institute of Biological Products
  62. 8.11.1 Chengdu Institute of Biological Products Company Information
  63. 8.11.2 Chengdu Institute of Biological Products Business Overview
  64. 8.11.3 Chengdu Institute of Biological Products Filgrastim and Biosimilars Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Chengdu Institute of Biological Products Filgrastim and Biosimilars Product Portfolio
  66. 8.11.5 Chengdu Institute of Biological Products Recent Developments
  67. 8.12 SL Pharm
  68. 8.12.1 SL Pharm Company Information
  69. 8.12.2 SL Pharm Business Overview
  70. 8.12.3 SL Pharm Filgrastim and Biosimilars Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 SL Pharm Filgrastim and Biosimilars Product Portfolio
  72. 8.12.5 SL Pharm Recent Developments
  73. 8.13 Teva
  74. 8.13.1 Teva Company Information
  75. 8.13.2 Teva Business Overview
  76. 8.13.3 Teva Filgrastim and Biosimilars Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Teva Filgrastim and Biosimilars Product Portfolio
  78. 8.13.5 Teva Recent Developments
  79. 8.14 Tanvex BioPharma
  80. 8.14.1 Tanvex BioPharma Company Information
  81. 8.14.2 Tanvex BioPharma Business Overview
  82. 8.14.3 Tanvex BioPharma Filgrastim and Biosimilars Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Tanvex BioPharma Filgrastim and Biosimilars Product Portfolio
  84. 8.14.5 Tanvex BioPharma Recent Developments
  85. 8.15 Sandoz
  86. 8.15.1 Sandoz Company Information
  87. 8.15.2 Sandoz Business Overview
  88. 8.15.3 Sandoz Filgrastim and Biosimilars Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Sandoz Filgrastim and Biosimilars Product Portfolio
  90. 8.15.5 Sandoz Recent Developments
  91. 8.16 Pfizer
  92. 8.16.1 Pfizer Company Information
  93. 8.16.2 Pfizer Business Overview
  94. 8.16.3 Pfizer Filgrastim and Biosimilars Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Pfizer Filgrastim and Biosimilars Product Portfolio
  96. 8.16.5 Pfizer Recent Developments
  97. 8.17 Kashiv BioSciences
  98. 8.17.1 Kashiv BioSciences Company Information
  99. 8.17.2 Kashiv BioSciences Business Overview
  100. 8.17.3 Kashiv BioSciences Filgrastim and Biosimilars Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Kashiv BioSciences Filgrastim and Biosimilars Product Portfolio
  102. 8.17.5 Kashiv BioSciences Recent Developments
  103. 8.18 Amgen
  104. 8.18.1 Amgen Company Information
  105. 8.18.2 Amgen Business Overview
  106. 8.18.3 Amgen Filgrastim and Biosimilars Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Amgen Filgrastim and Biosimilars Product Portfolio
  108. 8.18.5 Amgen Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Filgrastim and Biosimilars Value Chain Analysis
  2. 9.1.1 Filgrastim and Biosimilars Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Filgrastim and Biosimilars Sales Mode & Process
  6. 9.2 Filgrastim and Biosimilars Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Filgrastim and Biosimilars Distributors
  9. 9.2.3 Filgrastim and Biosimilars Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst